

## Product datasheet for **TL308557V**

### TUSC3 Human shRNA Lentiviral Particle (Locus ID 7991)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	TUSC3 Human shRNA Lentiviral Particle (Locus ID 7991)
Locus ID:	7991
Synonyms:	D8S1992; M33; MagT2; MRT7; MRT22; N33; OST3A; SLC58A2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	TUSC3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_006765</a> , <a href="#">NM_178234</a> , <a href="#">NM_001356429</a> , <a href="#">NM_178234.1</a> , <a href="#">NM_178234.2</a> , <a href="#">NM_006765.1</a> , <a href="#">NM_006765.2</a> , <a href="#">NM_006765.3</a> , <a href="#">BC010370</a> , <a href="#">BC010370.1</a> , <a href="#">NM_006765.4</a>
UniProt ID:	<a href="#">Q13454</a>
Summary:	This gene encodes a protein that has been associated with several biological functions including cellular magnesium uptake, protein glycosylation and embryonic development. This protein localizes to the endoplasmic reticulum and acts as a component of the oligosaccharyl transferase complex which is responsible for N-linked protein glycosylation. This gene is a candidate tumor suppressor gene. Homozygous mutations in this gene are associated with autosomal recessive nonsyndromic mental retardation-7 and in the proliferation and invasiveness of several cancers including metastatic pancreatic cancer, ovarian cancer and glioblastoma multiform. [provided by RefSeq, Oct 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).